Understanding risk and protective factors associated with opioid misuse among at-risk adolescents and young adults in the emergency department
Abstract
BACKGROUND: Opioid misuse/opioid use disorder prevention strategies tailored for risk and protective factors are needed among adolescents and young adults (AYAs). We describe baseline risk/protective factors related to opioid misuse among at-risk AYAs who attended Emergency Departments (EDs) enrolled in a randomized controlled trial.
METHODS: People who recently visited an ED (ages 16-30) and self-reported 1) past-year prescription opioid use+a risk factor for misuse (i.e., drug use, binge drinking, depression symptoms, suicide risk) or 2) heroin or prescription opioid misuse at screening were enrolled. Measures assessed background characteristics and risk/protective factors. Analyses compared participants based on whether they reported opioid misuse or were at-risk for misuse.
RESULTS: We enrolled 1155 people (27.5 % male); 79.5 % reported opioid use+risk factor and 20.5 % reported opioid misuse. In unadjusted analyses, relative to those with opioid use+risk factor, those with opioid misuse were significantly more likely to report: male sex, Black/African American race, receiving public assistance, food insecurity, stronger opioid use motives, greater substance use, a prior suicide attempt, violence involvement, and greater impulsivity. They also reported lower social support, prosocial activities, and self-efficacy to avoid substances. In adjusted analyses, those with opioid misuse were significantly more likely to be male, have greater alcohol and other substance use, and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,155 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.